GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 104
- Registration Number
- NCT03893565
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT03874234
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT03866187
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
A Study to Evaluate the Safety, Effectiveness and Impact of the GlaxoSmithKline Biologicals' Malaria Vaccine- RTS, S/AS01E in Young Children in Sub-Saharan Africa
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78000
- Registration Number
- NCT03855995
- Locations
- π²πΌ
GSK Investigational Site, Mangochi, Malawi
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT03848845
- Locations
- πͺπΈ
GSK Investigational Site, Salamanca, Spain
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03843359
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03828292
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naΓ―ve Adults
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT03824236
- Locations
- πΊπΈ
GSK Investigational Site, Silver Spring, Maryland, United States
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
Phase 1
Completed
- Conditions
- Interventions
- Drug: Placebo (Saline solution)Biological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01EBiological: RSV Vaccine (GSK3844766A) unadjuvanted low doseBiological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01BBiological: RSV Vaccine (GSK3844766A) unadjuvanted high doseBiological: RSV Vaccine (GSK3844766A) unadjuvanted medium doseBiological: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01BBiological: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01EBiological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01BBiological: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1053
- Registration Number
- NCT03814590
- Locations
- π§πͺ
GSK Investigational Site, Wilrijk, Belgium
Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT03809910
- Locations
- π¨π¦
GSK Investigational Site, Mississauga, Canada
Β© Copyright 2024. All Rights Reserved by MedPath